$
18. 81
+0.47
+2.5627%
$
508.7M Market Cap
- P/E Ratio
- Div Yield
44,162 Volume
- Eps
$ 18.34
Previous Close Investors:
Want to track CBIO and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Crescent Biopharma: Chasing The Summit Hype
Crescent Biopharma is an early-stage biotech with a promising PD-1/VEGF bispecific antibody, aiming for first-in-human trials in late 2025. The company is well-funded, with over $150 million in cash and a manageable burn rate, supporting operations for 2–3 years. Risks include being behind competitors and the unproven clinical potential of their lead candidate, but sector hype remains strong.
Seekingalpha | 9 months ago
